加利福尼亚州尔湾市,2024 年 8 月 14 日 (环球新闻社)——Eledon Pharmaceuticals, Inc.(“Eledon”)今天公布了其 2024 年第二季度的近期业务亮点。“由于我们的超额认购,我们进入下半年时资产负债表强劲。5000万美元私募融资后,我们对第二阶段 BESTOW 试验的进展和移植界的反响感到非常鼓舞,该试验仍有望在今...
At Eledon, our mission is One Transplant for Life. Our Mission? One Transplant for Life. Eledon is committed to ensuring the greatest gift will keep on giving. Eledon is dedicated to “One Transplant For Life” to significantly improve both the longevity of the organ and the overall healt...
Eledon Pharmaceuticals (ELDN) 宣布,其研究性抗 CD40L 抗体 Tegoprubart 被用作一名最近接受转基因猪移植肾脏的患者的免疫抑制治疗方案的关键组成部分。该手术于 2025 年 1 月 25 日在麻省总医院 (MGH) 进行,是与 eGenesis 合作进行的,是 MGH 的第二例肾异种移植手术。MGH 的第一次异种移植于 2024 年 3...
One Transplant for Life.Eledon is committed to ensuring the greatest gift will keep on giving. Eledon is dedicated to “One Transplant For Life” to significantly improve both the longevity of the organ and the overall health and quality of life for transplant recipients so that a donor’s ...
必应词典为您提供eledon的释义,网络释义: 宜悦朵;依莱顿;依莱当;
据InvestingPro数据显示,市值2.8454亿美元、过去一年股价上涨170%的生物科技公司Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)宣布,其研究性药物tegoprubart在2025年1月25日成功用于一例开创性的基因改造猪-人肾脏移植手术。该手术在Massachusetts General Hospital (MGH)进行,并与eGenesis合作完成,这标志着异种器官移植领...
雪球为您提供Eledon(ELDN)股票实时行情,资金流向,新闻资讯,研究报告,社区互动,交易信息,个股点评,公告,财务指标分析等与Eledon(ELDN)股票相关的信息与服务.
IRVINE, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink P...
--Eledon Pharmaceuticals, Inc. today announced that Steve Perrin, Ph.D., Chief Scientific Officer and President, will participate in a fireside chat at the upcoming Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 2:20 p.m. ET
Novus Therapeutics/ Eledon Pharmaceuticals是一家以患者为中心的临床阶段生物制药公司,致力于为器官和细胞移植、自身免疫性疾病和神经退行性疾病开发创新和有效的治疗方法。 2021年1月4日,Novus Therapeutics 宣布更名为 Eledon Pharmaceuticals。将于明天开始在纳斯达克交易所交易,股票代码为“ELDN”。